Mycobacterial disease in patients with rheumatic disease
Authors:
- Jakko van IngenJIJakko van Ingen
- Martin J BoereeMBMartin J Boeree
- Pn Richard DekhuijzenPDPn Richard Dekhuijzen
- Dick van SoolingenDSDick van Soolingen
- 1 December 2008
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 4 (12) , 649-656
Abstract
This Review focuses on the emergence of mycobacterial disease in patients undergoing treatment for rheumatic disease with four new drug classes--tumor necrosis factor (TNF) inhibitors, human interleukin (IL)-1 receptor antagonists, anti-CD20 antibodies and CD4(+) T-cell costimulation modulators--collectively referred to as biologic agents. Mycobacterial disease is a major cause of severe infection in patients undergoing anti-TNF therapy. Reports are now emerging of an association between mycobacterial infection and antirheumatic treatment with anti-IL-1 or anti-CD20 antibodies. Although tuberculosis is the most common mycobacterial disease, nontuberculous mycobacterial (NTM) disease is an increasingly recognized problem in this setting. Among the antirheumatic drugs currently in development, agents that target IL-17, IL-23, Janus kinase-signal transducers and activators of transcription signaling, and metalloproteinases are likely to confer an increased risk of mycobacterial disease. Although screening and preventive treatments have lowered the incidence of active tuberculosis, these tools are not applicable to patients with NTM disease. All patients receiving drugs associated with an increased risk of mycobacterial disease should be carefully monitored, and suspect lesions should undergo Mycobacterium culture. Further studies are needed to determine the prevalence of NTM disease in this setting, and to evaluate the safety of simultaneous anti-TNF and antimycobacterial treatment.Keywords
This publication has 54 references indexed in Scilit:
- Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trialsAnnals of the Rheumatic Diseases, 2009
- Mycobacterium xenopi Clinical Relevance and Determinants, the NetherlandsEmerging Infectious Diseases, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?Nature Clinical Practice Rheumatology, 2008
- IL-23 and IL-17 in tuberculosisCytokine, 2008
- Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapyAnnals of the Rheumatic Diseases, 2007
- Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanerceptThorax, 2007
- Role for Matrix Metalloproteinase 9 in Granuloma Formation during PulmonaryMycobacterium tuberculosisInfectionInfection and Immunity, 2006
- Infliximab for Rheumatoid Arthritis in a Patient with TuberculosisNew England Journal of Medicine, 2006
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004